On Tuesday, Keros Therapeutics Inc (NASDAQ: KROS) opened lower -2.39% from the last session, before settling in for the closing price of $17.12. Price fluctuations for KROS have ranged from $15.67 to $73.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -40.00% over the last five years. Company’s average yearly earnings per share was noted 0.22% at the time writing. With a float of $30.96 million, this company’s outstanding shares have now reached $39.26 million.
The firm has a total of 136 workers. Let’s measure their productivity. In terms of profitability, gross margin is -27.5%, operating margin of -31341.63%, and the pretax margin is -27890.94%.
Keros Therapeutics Inc (KROS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Keros Therapeutics Inc is 23.56%, while institutional ownership is 79.02%. The most recent insider transaction that took place on Aug 13 ’24, was worth 11,002,500. In this transaction Director of this company sold 250,000 shares at a rate of $44.01, taking the stock ownership to the 119,522 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Director sold 250,000 for $44.01, making the entire transaction worth $11,002,500. This insider now owns 119,522 shares in total.
Keros Therapeutics Inc (KROS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.80% during the next five years compared to -111.11% drop over the previous five years of trading.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
Check out the current performance indicators for Keros Therapeutics Inc (KROS). In the past quarter, the stock posted a quick ratio of 19.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1041.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.21, a number that is poised to hit -1.36 in the next quarter and is forecasted to reach -5.03 in one year’s time.
Technical Analysis of Keros Therapeutics Inc (KROS)
Analysing the last 5-days average volume posted by the [Keros Therapeutics Inc, KROS], we can find that recorded value of 1.32 million was better than the volume posted last year of 0.49 million. As of the previous 9 days, the stock’s Stochastic %D was 8.19%. Additionally, its Average True Range was 4.46.
During the past 100 days, Keros Therapeutics Inc’s (KROS) raw stochastic average was set at 1.83%, which indicates a significant increase from 1.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 534.83% in the past 14 days, which was higher than the 214.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $53.27, while its 200-day Moving Average is $53.34. Now, the first resistance to watch is $17.01. This is followed by the second major resistance level at $17.31. The third major resistance level sits at $17.50. If the price goes on to break the first support level at $16.52, it is likely to go to the next support level at $16.33. Now, if the price goes above the second support level, the third support stands at $16.03.
Keros Therapeutics Inc (NASDAQ: KROS) Key Stats
There are currently 40,507K shares outstanding in the company with a market cap of 676.88 million. Presently, the company’s annual sales total 150 K according to its annual income of -152,990 K. Last quarter, the company’s sales amounted to 390 K and its income totaled -52,960 K.
